XOMA (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average of $22.10

XOMA Co. (NASDAQ:XOMAGet Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $22.10 and traded as high as $24.20. XOMA shares last traded at $24.05, with a volume of 6,026 shares traded.

Wall Street Analysts Forecast Growth

XOMA has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $74.00 price target on shares of XOMA in a research note on Friday, May 31st. SVB Leerink assumed coverage on shares of XOMA in a research note on Monday, April 29th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Leerink Partnrs restated an “outperform” rating on shares of XOMA in a research note on Monday, April 29th.

Read Our Latest Stock Analysis on XOMA

XOMA Price Performance

The company has a market cap of $279.94 million, a price-to-earnings ratio of -6.14 and a beta of 0.85. The company has a current ratio of 9.45, a quick ratio of 9.45 and a debt-to-equity ratio of 1.39. The company’s 50 day moving average price is $25.20 and its 200 day moving average price is $22.10.

XOMA (NASDAQ:XOMAGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). The company had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0.96 million. XOMA had a negative net margin of 705.23% and a negative return on equity of 26.00%. Equities research analysts forecast that XOMA Co. will post -1.76 earnings per share for the current year.

Hedge Funds Weigh In On XOMA

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its holdings in XOMA by 55.6% during the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,266 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in XOMA during the 1st quarter valued at about $212,000. Finally, Stonepine Capital Management LLC increased its holdings in XOMA by 25.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 436,602 shares of the biotechnology company’s stock valued at $6,152,000 after acquiring an additional 87,203 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Featured Articles

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.